VideoHIV17th International Workshop on Pediatrics & HIV 2025Abstract #10 Outcomes of Children and Young Adolescents Receiving ART Under Family-Based DSD Model at Largest Public ART Clinic in Lilongwe, Malawi - Petros P.M. TemboView Video
MMMauricio MartinsBSc, PhDSlidesetHIV17th International Workshop on Pediatrics & HIV 2025 Gene Therapy and Remission - Mauricio MartinsView Slideset
MMMauricio MartinsBSc, PhDVideoHIV17th International Workshop on Pediatrics & HIV 2025 Gene Therapy and Remission - Mauricio MartinsView Video
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #11 Predictors of Treatment Failure in Children Living with HIV Starting First-Line Antiretroviral Therapy in the ODYSSEY Trial - James WyncollView Slideset
VideoHIV17th International Workshop on Pediatrics & HIV 2025Abstract #11 Predictors of Treatment Failure in Children Living with HIV Starting First-Line Antiretroviral Therapy in the ODYSSEY Trial - James WyncollView Video
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #12 Factors Associated with HIV-1 DNA Dynamics in Early Treated Children with Perinatal HIV - Alfredo Tagarro GarciaView Slideset
VideoHIV17th International Workshop on Pediatrics & HIV 2025Abstract #12 Factors Associated with HIV-1 DNA Dynamics in Early Treated Children with Perinatal HIV - Alfredo Tagarro GarciaView Video
HMHilda MujuruMBChB, MMed Paeds, MSc Clin EpiSlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #13 Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide (F/TAF) Plus Cobicistat-Boosted Protease Inhibitors in Children with HIV-1 Aged 2-<12 Years and Weighing 14-<40 kg: Week 48 Outcomes - Hilda Angela MujuruView Slideset
HMHilda MujuruMBChB, MMed Paeds, MSc Clin EpiVideoHIV17th International Workshop on Pediatrics & HIV 2025Abstract #13 Efficacy and Safety of Emtricitabine/Tenofovir Alafenamide (F/TAF) Plus Cobicistat-Boosted Protease Inhibitors in Children with HIV-1 Aged 2-<12 Years and Weighing 14-<40 kg: Week 48 Outcomes - Hilda Angela MujuruView Video
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #14 Effectiveness and Safety of Dolutegravir (DTG) in Infants and Children Aged Under 12-Years at Start of DTG in Europe and Thailand - Intira Jeannie CollinsView Slideset
VideoHIV17th International Workshop on Pediatrics & HIV 2025Abstract #14 Effectiveness and Safety of Dolutegravir (DTG) in Infants and Children Aged Under 12-Years at Start of DTG in Europe and Thailand - Intira Jeannie CollinsView Video
SlidesetHIV17th International Workshop on Pediatrics & HIV 2025Abstract #15 Efficacy of Second-Line Dolutegravir- versus Boosted Protease Inhibitor-Based ART in Children and Adolescents Living with HIV at 96 and 144 Weeks: Pooled Analysis of the ODYSSEY and CHAPAS-4 Trials - Pauline AmugeView Slideset
